By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Molecular diagnostics developer Asuragen said today that Biomedical Diagnostics (BMD) will distribute its cancer assays in France.

The agreement covers Asuragen's Signature Oncology Portfolio, a line of multiplex assays used to detect mutations in solid and hematologic malignancies. The tests use RT-PCR and multiplex detection using the Luminex 100 or 200 systems.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.